News Vinay Prasad returns to FDA In a new spin on the concept of the FDA's 'revolving door', Vinay Prasad is back as head of CBER, just over a week after leaving the role.
Sales & Marketing Biopharma's costly blind spot: Exhausted minds, expensive mi... Burnout isn't just a personal issue anymore; it’s a strategic imperative.
News Tidmarsh to stand in for Prasad's role at CBER Following Vinay Prasad's abrupt departure as CBER director, FDA has asked CDER head George Tidmarsh to take on both roles while a successor is sought.
News NICE CEO to step down by year-end Sam Roberts is stepping down from the role of NICE CEO to support her children through a difficult time, and a search for her replacement is underway.
News Vinay Prasad abruptly departs from the FDA The disruption at the FDA continues with the departure of CBER director Vinay Prasad, less than three months after taking on the role.
News Novo Nordisk slumps as it cuts sales forecast, names new CEO Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
